NIKKEI 225
38,385.73 +29.67 (+0.08%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.60 +0.58 (+0.74%) GOLD FUTURES
2,392.40 +32.50 (+1.38%) DOW
39,819.72 +261.61 (+0.66%) Bitcoin GBP
51,611.38 +3,278.28 (+6.78%)
NBIX May 2024 145.000 call
| Previous close | 0.0800 |
| Open | 0.2000 |
| Bid | 0.0000 |
| Ask | 0.4500 |
| Strike | 145.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.2000 - 0.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.32k |
PR NewswireNeurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Diurnal Ltd., a Neurocrine Biosciences company, presented baseline data from the CAHtalyst™ Phase 3 studies of crinecerfont in adult and pediatric patients with congenital adrenal hyperplasia (CAH), and modified-release hydrocortisone (Chronocort®) data for a Phase 2 clinical study (CHAMPAIN) in participants with primary adrenal insufficiency and in a Phase 3 extension study in CAH. These data, along with several additional posters were presented a
Investor's Business DailyHow Neurocrine Is Stacking Up Wins In 2024 — And Outperforming Peers
Neurocrine Biosciences is making good on its promise to diversify from Ingrezza. Meanwhile, the biotech stock is angling for a record.
- PR Newswire
Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present CAHtalyst™ Adult Phase 3 clinical study baseline characteristics for adults with congenital adrenal hyperplasia (CAH) enrolled in the study, as well as data from a comprehensive literature review assessing the impact of supraphysiologic glucocorticoid (GC) doses on psychiatric disorders and cognition in patients with CAH.
